SAB Biotherapeutics
SABS
SABS
76 hedge funds and large institutions have $265M invested in SAB Biotherapeutics in 2026 Q1 according to their latest regulatory filings, with 34 funds opening new positions, 24 increasing their positions, 7 reducing their positions, and 5 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
59.46% more ownership
Funds ownership: 76.34% → 135.8% (+59%)
58% more funds holding
Funds holding: 48 → 76 (+28)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Holders
76
Holding in Top 10
1
Calls
$611K
Puts
$283K
Top Buyers
| 1 | +$31.8M | |
| 2 | +$22.4M | |
| 3 | +$13.6M | |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
+$13.1M |
| 5 |
Millennium Management
New York
|
+$10.8M |
Top Sellers
| 1 | -$5.12M | |
| 2 | -$100K | |
| 3 | -$98.5K | |
| 4 |
SAM
Simplify Asset Management
Las Vegas,
Nevada
|
-$83.7K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$70.4K |
